Meeder Asset Management Inc Aldeyra Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$1.97 - $5.05 $2,054 - $5,267	-1,043 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.62 - $6.4 $8,670 - $34,252	-5,352 Reduced 83.69%	1,043 $3,000
Q4 2019 Feb 13, 2020	SELL	$4.73 - $7.98 $19,170 - $32,342	-4,053 Reduced 38.79%	6,395 $38,000
Q3 2019 Oct 17, 2019	BUY	$4.41 - $6.12 $41,846 - $58,072	9,489 Added 989.47%	10,448 $54,000
Q2 2019 Aug 05, 2019	SELL	$6.0 - $9.0 $49,956 - $74,934	-8,326 Reduced 89.67%	959 $6,000
Q1 2019 Apr 16, 2019	BUY	$7.14 - $9.85 $2,834 - $3,910	397 Added 4.47%	9,285 $84,000
Q4 2018 Jan 17, 2019	BUY	$7.26 - $13.29 $35,007 - $64,084	4,822 Added 118.59%	8,888 $74,000
Q3 2018 Nov 02, 2018	BUY	$6.8 - $14.35 $27,648 - $58,347	4,066 New	4,066 $0

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.